<DOC>
	<DOCNO>NCT01038154</DOCNO>
	<brief_summary>The survival esophageal cancer stomach cancer ( EGC ) 5 year less 30 % . Pravastatin potent inhibitor HMG-CoA reductase inhibitor show increased survival patient advance hepatocellular carcinoma . The objective evaluate efficacy treatment ( increase survival recurrence-free period disease ) pravastatin patient advance EGC . The investigator design randomize , control open . Advanced stage consider patient T4 N1 M1 accord TNM classification . It estimate sample size per treatment arm 73 patient ( 146 patient total ) . Randomization do stratify location ( CE CG ) . All patient receive hatitual treatment ( surgery / chemotherapy / radiotherapy / palliative ) clinical condition . The experimental group receive one tablet 40 mg pravastatin orally every 24 hour ( breakfast ) 2 year . There monthly monitoring patient least 2 year include analytics . Every 2 month abdominal-pelvic CT scan ass progression treatment response .</brief_summary>
	<brief_title>Study Evaluate Efficacy Pravastatin Survival Recurrence Advanced Gastroesophageal Cancer</brief_title>
	<detailed_description>1 . Design : A randomized , control , open , parallel group study assess survival disease-free period progression patient advance CGE period 2 year . 2 . Under study : Patients diagnose histology first time , advanced-stage CGE fulfilling inclusion criterion none exclusion criterion propose Hospital Donostia ( San Sebastian ) Hospital de Basurto ( Bilbao ) . 3 . Inclusion criterion : old 18 year , esophageal gastric cancer histologically confirm ( squamous adenocarcinoma ) first time , advanced stage ( T4 N1 M1 ) accord fourth edition TNM classification signing inform consent 4 . Exclusion criterion : Patients routinely take ( 3 day week ) anti-inflammatory drug aspirin , patient receive oral anticoagulant , fibrates , cyclosporine oral contraceptive , patient hypersensitivity pravastatin , pregnant woman lactation , peripheral neuropathy grade 2 great , patient diagnose previous 5 year skin cancer tumor melanoma carcinoma situ cervix bladder , patient receive chemotherapy radiotherapy tumor patient laboratory parameter start present study transaminase alkaline phosphatase twice normal value , patient platelet count less 100.000/mm3 , absolute neutrophil count 1000/mm3 , patient evidence bleed diathesis coagulopathy , patient heart failure NYHA grade II , patient creatinine great 2 mg / dL , patient 75 year , asthmatic , patient physical mental disability , patient alcoholism patient disease hereditary muscle 5 . Intervention : Patients randomize two group : - Experimental Group : You receive one tablet 40 mg pravastatin Cinfa EFG , orally every 24 hour ( breakfast ) 2 year . - Control Group : receive pravastatin . All patient receive prescribe treatment ( surgery / chemotherapy / radiotherapy / palliative ) base stage clinical situation .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Pravastatin</mesh_term>
	<criteria>Over 18 year , Esophageal gastric cancer histologically confirm ( squamous adenocarcinoma ) first time , Advanced stage ( T4 N1 M1 ) accord fourth edition TNM classification , Signing inform consent . Patients routinely take ( 3 day week ) antiinflammatory drug aspirin , Patients receive oral anticoagulant , fibrates , cyclosporine oral contraceptive , Patients hypersensitivity pravastatin , Pregnant lactate woman , Peripheral neuropathy grade 2 great , Patients diagnose previous 5 year skin cancer tumor melanoma carcinoma situ cervix bladder , Patients receive chemotherapy radiotherapy another type tumor , Patients laboratory parameter start present study transaminase alkaline phosphatase twice normal value , Patients platelet count less 100.000/mm3 , absolute neutrophil count 1000/mm3 , Patients evidence bleed diathesis coagulopathy , Patients heart failure NYHA grade II , Patients creatinine great 2 mg / dL , Patients 75 year , Asthmatics , Patients physical mental disability , Patients alcoholism , OR Patients hereditary muscle disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>advanced esophageal cancer stomach cancer</keyword>
	<keyword>Pravastatin</keyword>
	<keyword>Survival</keyword>
	<keyword>adverse effect</keyword>
</DOC>